Avidity biosciences reports first quarter 2025 financial results and recent highlights

On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the fortitude™ trial in the second quarter positive topline del-zota data further supports first bla submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for dmd44, dm1 and fshd  executing on global commercial infrastructure development and on track with preparations for first potential commercial launch in u.s. in 2026 strong balance sheet supports execution across three late-stage clinical programs and commercial launch preparations with cash runway into mid-2027 san diego , may 8, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™) to profoundly improve people's lives, today reported financial results for the first quarter ended march 31, 2025, highlighting recent progress. "we continue to build on the consistent and reproducible data readouts from our platform across all three of our clinical programs for dmd44, dm1 and fshd, and are executing on our transition to become a global commercial organization.
RNA Ratings Summary
RNA Quant Ranking